Just like ENMD, this stock is poised to rocket on Thursday the 21st of May.
Advanced Viral Research Corp.
Announces Extension of Research
Agreement with National Cancer
Institute
Advanced Viral Research Corp. (OTC Bulletin
Board: ADVR) today announced that its Materials
Transfer Agreement-Cooperative Research and
Development Agreement (MTA-CRADA) with the
National Cancer Institute (NCI) for research with
ADVR's flagship drug, Reticulose, has been
extended for one year, beginning March 4, 1998
and ending March 3, 1999.
Reticulose is a non-toxic immunomodulator that has
been shown to have a broad spectrum of antiviral
therapeutic effects in patients. At the NCI,
Reticulose is being used to study the basic
mechanisms of immune responses. This scientific
research is led by Dr. Howard Young, Section
Chief in the Laboratory of Experimental
Immunology at the NCI, an expert on
interferon-gamma. Using kidney tumor model
systems, Dr. Young is investigating the anti-tumor
activity of Reticulose. In addition, Dr. Young and
his colleagues will study the effects of Reticulose on
inflammation associated with rheumatoid arthritis.
"The extension of this collaborative agreement
between Advanced Viral Research Corp. and one
of the premier immunology research laboratories is
an important event. We expect these research
efforts to provide new insights into the therapeutic
potentials, and uses of Reticulose while adding to
our basic understanding of the workings of the
immune system," stated Dr. Shalom Z. Hirschman,
President and Chief Executive Officer of Advanced
Viral Research Corp.
NOTE the NCI's request to another year of RETICULOSE research after they already
invested more than 1 year of manpower and money. |
